Laidlaw & Co. Downgrades Evofem Biosciences to Hold
Portfolio Pulse from Benzinga Newsdesk
Laidlaw & Co. analyst Yale Jen has downgraded Evofem Biosciences (EVFM) from Buy to Hold, indicating a change in the firm's outlook on the stock.
December 13, 2023 | 9:25 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Evofem Biosciences was downgraded by Laidlaw & Co. from Buy to Hold, which may influence investors' perception and could potentially affect the stock's performance in the short term.
Downgrades by analysts can lead to a neutral short-term impact on the stock price as it may already reflect the current market sentiment and performance issues that prompted the downgrade. However, the downgrade does not necessarily predict a decline, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100